Insider Buying: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Major Shareholder Buys $1,500,000.00 in Stock

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) major shareholder Aisling Capital Iv, Lp bought 2,500,000 shares of the company’s stock in a transaction dated Monday, July 15th. The stock was bought at an average cost of $0.60 per share, with a total value of $1,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

SNSS stock opened at $0.90 on Thursday. The company’s fifty day simple moving average is $0.74. Sunesis Pharmaceuticals, Inc. has a fifty-two week low of $0.20 and a fifty-two week high of $2.60. The firm has a market cap of $62.37 million, a PE ratio of -1.20 and a beta of 2.75.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.08. Equities analysts expect that Sunesis Pharmaceuticals, Inc. will post -0.43 earnings per share for the current year.

A number of equities analysts have recently issued reports on the company. ValuEngine cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, June 17th. Cowen reaffirmed a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Sunday, June 16th. Finally, Zacks Investment Research cut HEXO from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $3.08.

Hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC acquired a new stake in Sunesis Pharmaceuticals during the 1st quarter valued at $25,000. Fosun International Ltd acquired a new stake in Sunesis Pharmaceuticals during the 1st quarter valued at $863,000. Finally, Aisling Capital Management LP increased its holdings in Sunesis Pharmaceuticals by 192.3% during the 1st quarter. Aisling Capital Management LP now owns 7,600,000 shares of the biopharmaceutical company’s stock valued at $9,234,000 after purchasing an additional 5,000,000 shares in the last quarter. 43.10% of the stock is owned by hedge funds and other institutional investors.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Featured Article: What defines an oversold asset?

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with's FREE daily email newsletter.